Share:
Schizophrenia is the most common psychotic disease with a global prevalence in about 1% of the population, affecting approximately 3.5 million people in the U.S. and 20 million globally. Despite the high prevalence, there is currently no therapy that adequately addresses the complex mental disorder.
Current antipsychotics prescribed for schizophrenia are plagued with suboptimal efficacy, poor tolerability, adverse effects and abnormally high dropout rates.
As a result of suboptimal efficacy, the major symptoms of schizophrenia, such as chronic mood symptoms and cognitive dysfunction, are not adequately addressed to date. In addition, approved antipsychotics are reported to cause adverse effects at varying degrees including extrapyramidal symptoms (EPS), akathisia, obesity, diabetes, cholesterol and sexual dysfunction.
Reviva Pharmaceuticals Holdings, Inc Reports 2020 Financial Results and Provides Corporate Update biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Share:
Combined Company to Trade on NASDAQ Post-closing under Tickers: RVPH and RVPHW
NEW YORK and CUPERTINO, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (
Reviva Holdings ), as the successor to Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (
Tenzing ) (NASDAQ:TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (
Reviva ), a California-based clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced the completion of their previously announced business combination of the two companies (the